Geode Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $112M | Buy |
558,934
+65,345
| +13% | +$12.9M | 0.01% | 1016 |
|
|
2025
Q4 | $93.3M | Buy |
493,589
+19,400
| +4% | +$3.73M | 0.01% | 1126 |
|
|
2025
Q3 | $84M | Sell |
474,189
-14,589
| -3% | -$2.17M | 0.01% | 1183 |
|
|
2025
Q2 | $55.6M | Buy |
488,778
+24,326
| +5% | +$2.6M | ﹤0.01% | 1368 |
|
|
2025
Q1 | $48.8M | Buy |
464,452
+26,011
| +6% | +$2.94M | ﹤0.01% | 1390 |
|
|
2024
Q4 | $47M | Buy |
438,441
+10,171
| +2% | +$1.15M | ﹤0.01% | 1476 |
|
|
2024
Q3 | $42.9M | Buy |
428,270
+22,495
| +6% | +$2.26M | ﹤0.01% | 1515 |
|
|
2024
Q2 | $34.2M | Buy |
405,775
+24,805
| +7% | +$1.97M | ﹤0.01% | 1617 |
|
|
2024
Q1 | $27.9M | Buy |
380,970
+10,155
| +3% | +$749K | ﹤0.01% | 1726 |
|
|
2023
Q4 | $26.5M | Buy |
370,815
+18,194
| +5% | +$1.07M | ﹤0.01% | 1741 |
|
|
2023
Q3 | $21.1M | Buy |
352,621
+11,008
| +3% | +$725K | ﹤0.01% | 1787 |
|
|
2023
Q2 | $24.6M | Buy |
341,613
+24,814
| +8% | +$1.86M | ﹤0.01% | 1713 |
|
|
2023
Q1 | $23.3M | Buy |
316,799
+16,129
| +5% | +$1.15M | ﹤0.01% | 1686 |
|
|
2022
Q4 | $20.1M | Sell |
300,670
-164,376
| -35% | -$10.7M | ﹤0.01% | 1770 |
|
|
2022
Q3 | $25M | Sell |
465,046
-986
| -0.2% | -$58K | ﹤0.01% | 1571 |
|
|
2022
Q2 | $25.9M | Sell |
466,032
-15,825
| -3% | -$898K | ﹤0.01% | 1569 |
|
|
2022
Q1 | $33.8M | Buy |
481,857
+25,542
| +6% | +$1.85M | ﹤0.01% | 1531 |
|
|
2021
Q4 | $44M | Buy |
456,315
+13,863
| +3% | +$1.28M | 0.01% | 1397 |
|
|
2021
Q3 | $38.5M | Sell |
442,452
-2,477
| -0.6% | -$192K | 0.01% | 1492 |
|
|
2021
Q2 | $36.4M | Buy |
444,929
+23,539
| +6% | +$1.96M | 0.01% | 1572 |
|
|
2021
Q1 | $40.1M | Buy |
421,390
+46,597
| +12% | +$4.4M | 0.01% | 1404 |
|
|
2020
Q4 | $23.3M | Buy |
374,793
+3,160
| +0.9% | +$180K | ﹤0.01% | 1629 |
|
|
2020
Q3 | $22.1M | Sell |
371,633
-14,502
| -4% | -$990K | ﹤0.01% | 1469 |
|
|
2020
Q2 | $26.9M | Sell |
386,135
-30,361
| -7% | -$1.92M | 0.01% | 1279 |
|
|
2020
Q1 | $18.9M | Buy |
416,496
+15,897
| +4% | +$901K | ﹤0.01% | 1328 |
|
|
2019
Q4 | $26.1M | Sell |
400,599
-12,165
| -3% | -$813K | 0.01% | 1387 |
|
|
2019
Q3 | $25.6M | Sell |
412,764
-7,650
| -2% | -$480K | 0.01% | 1310 |
|
|
2019
Q2 | $29.9M | Buy |
420,414
+4,038
| +1% | +$297K | 0.01% | 1199 |
|
|
2019
Q1 | $32.7M | Buy |
416,376
+18,095
| +5% | +$1.37M | 0.01% | 1086 |
|
|
2018
Q4 | $33.7M | Buy |
398,281
+33,292
| +9% | +$3.55M | 0.01% | 941 |
|
|
2018
Q3 | $62.5M | Buy |
364,989
+11,308
| +3% | +$1.7M | 0.02% | 698 |
|
|
2018
Q2 | $45.7M | Buy |
353,681
+36,404
| +11% | +$4.06M | 0.01% | 811 |
|
|
2018
Q1 | $32.7M | Buy |
317,277
+12,409
| +4% | +$1.23M | 0.01% | 954 |
|
|
2017
Q4 | $26M | Buy |
304,868
+16,039
| +6% | +$1.39M | 0.01% | 1086 |
|
|
2017
Q3 | $24.5M | Buy |
288,829
+3,081
| +1% | +$244K | 0.01% | 1086 |
|
|
2017
Q2 | $21.6M | Buy |
285,748
+27,308
| +11% | +$1.91M | 0.01% | 1117 |
|
|
2017
Q1 | $17.1M | Buy |
258,440
+10,804
| +4% | +$711K | 0.01% | 1269 |
|
|
2016
Q4 | $15.7M | Buy |
247,636
+7,927
| +3% | +$500K | 0.01% | 1269 |
|
|
2016
Q3 | $15.3M | Buy |
239,709
+5,911
| +3% | +$434K | 0.01% | 1192 |
|
|
2016
Q2 | $17.4M | Buy |
233,798
+22,805
| +11% | +$1.69M | 0.01% | 1039 |
|
|
2016
Q1 | $14.1K | Buy |
210,993
+4,252
| +2% | +$258K | 0.01% | 1138 |
|
|
2015
Q4 | $14M | Buy |
206,741
+5,752
| +3% | +$355K | 0.01% | 1134 |
|
|
2015
Q3 | $10.7M | Buy |
200,989
+571
| +0.3% | +$34.6K | 0.01% | 1294 |
|
|
2015
Q2 | $12.6M | Buy |
200,418
+12,853
| +7% | +$701K | 0.01% | 1245 |
|
|
2015
Q1 | $9.02M | Buy |
187,565
+2,556
| +1% | +$97.9K | 0.01% | 1466 |
|
|
2014
Q4 | $6.14M | Sell |
185,009
-18,971
| -9% | -$617K | ﹤0.01% | 1694 |
|
|
2014
Q3 | $5.98M | Buy |
203,980
+19,204
| +10% | +$637K | ﹤0.01% | 1643 |
|
|
2014
Q2 | $7.18M | Sell |
184,776
-14,293
| -7% | -$580K | ﹤0.01% | 1555 |
|
|
2014
Q1 | $8.35M | Buy |
199,069
+38,678
| +24% | +$1.61M | 0.01% | 1382 |
|
|
2013
Q4 | $5.26M | Buy |
160,391
+10,196
| +7% | +$332K | ﹤0.01% | 1665 |
|
|
2013
Q3 | $4.05M | Buy |
150,195
+8,176
| +6% | +$230K | ﹤0.01% | 1715 |
|
|
2013
Q2 | $3.31M | Buy |
+142,019
| New | +$2.55M | ﹤0.01% | 1718 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Geode Capital Management's LGND Position: Q1 2026 in Review
Geode Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 13% in Q1 2026, buying an estimated $12.9M and bringing the position to 558,934 shares worth $112M. The position accounts for 0.01% of the portfolio, ranked #1016.
Geode Capital Management first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Geode Capital Management held 558,934 shares of Ligand Pharmaceuticals worth $112M as of Q1 2026.
- Geode Capital Management bought 65,345 Ligand Pharmaceuticals shares in Q1 2026, an estimated $12.9M.
- Ligand Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #1016 holding.
- Geode Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.